Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC7 peptide is a cationic antimicrobial peptide (AMP) derived from the N-terminal region of the human low-molecular-weight salivary mucin, MUC7. It is primarily investigated for its potent antifungal and antibacterial properties, particularly against *Candida albicans*, *Streptococcus mutans*, and *Escherichia coli*. The peptide, most commonly studied as a 12-amino acid sequence (RKSYKCLHKRCR), exerts its effect through membrane perturbation and the activation of the calcium/calcineurin signaling pathway in fungal cells. While it has shown promise in preclinical research for conditions like oral candidiasis and dental caries, it remains in the early research phase and has not yet been advanced into formal clinical development by a commercial entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MUC7 peptide.